Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurinia Names CEO

This article was originally published in Scrip

Executive Summary

Aurinia Pharmaceuticals Inc. has appointed Charles Rowland CEO, replacing Stephen Zaruby who will be resigning as the company's CEO and from its board of directors. Rowland was vice president and chief financial officer (CFO) of ViroPharma Inc. until it was acquired by Shire PLC. in 2014. Prior to this, he held various leadership positions at biotech and pharma companies and most recently was interim co-CEO, executive vice president, CFO for Endo Pharmaceuticals Inc. Previously Rowland held positions at Biovail Corp., Breakaway Technologies Inc., Pharmacia Corp., Novartis AG and Bristol-Myers Squibb.

You may also be interested in...



Aurinia Has FDA OK For Phase III Voclosporin Trialing In Lupus Nephritis

Following consultations with the FDA, Canada's Aurinia Pharmaceuticals plans to run a single Phase III trial for voclosporin in lupus nephritis and then proceed to filing an NDA.

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel